Lilly, AZ start late-stage study of BACE inhibitor for AD

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) began the Phase II/III AMARANTH trial of AZD3293 to treat early Alzheimer's disease (AD).

The primary endpoint of the two-year, 1,500-patient trial is change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score from baseline to week 104. Data are expected in 2019. ...